Mark Fendrick, MD, Discusses Value-Based Insurance Design
Dr. Mark Fendrick, MD, Professor of Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan, Co-Editor-in-Chief, The American Journal of Managed Care, says that there are levers organizations and stakeholders can pull to achieve the goal of improving quality and value in cancer care. Dr. Fendrick discusses the importance of combining the supply side, or how you pay doctors, and the demand side of value, or consumer engagement. Dr. Fendrick also says that the goal of improved health and cost containment can be achieved when the two sides are combined.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
One billion dollars. That can be the list price for bringing a new cancer-fighting agent from preclinical design through approval by the US Food and Drug Administration, according to Michael R. Grever, MD, of the Ohio State University.
llicit drug use continues to be a prevalent and growing problem in the United States, and the use of newer substances is on the rise. Because of the increasing prevalence and “tweaking” of compounds to avoid detection, the identification of drug abuse by practitioners often relies on signs and symptoms. In this session, presenters reviewed some of these agents, including their history and their impact on those abusing them.
Retired general and former secretary of state Colin Powell discussed his thoughts on the US healthcare system and the role pharmacists play within it during his keynote address at the ASHP Midyear Clinical Meeting.
In this session, a sustainable business model for pharmacists practicing in an accountable care organization environment was described by Kelly Boesen, PharmD, BCPS, and Sandra Leal, PharmD, MPH, CDE, FAPhA, of the El Rio Health Center in Tucson, Arizona.
In the battle to control costs and out-of-pocket expenses for consumers, it would seem logical that doctors would choose the lower-cost drug. However, a report found that when given the choice, doctors chose the more expensive eye medicine over a lower cost option, even when both prescriptions provided the same effective treatment.
The federal health care exchange is incorrectly determining that some people are eligible for Medicaid when they clearly are not, leaving them with little chance to get the subsidized insurance they are entitled to as the Dec. 23 deadline for enrollment approaches.
Competition over healthcare prices and quality is coming. Transparency and the radical redesign of health insurance benefits will be its handmaiden. Companies such as General Electric are leading the way.